BN.com Gift Guide

Genentech: The Beginnings of Biotech [NOOK Book]

Overview

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the ...
See more details below
Genentech: The Beginnings of Biotech

Available on NOOK devices and apps  
  • NOOK Devices
  • Samsung Galaxy Tab 4 NOOK 7.0
  • Samsung Galaxy Tab 4 NOOK 10.1
  • NOOK HD Tablet
  • NOOK HD+ Tablet
  • NOOK eReaders
  • NOOK Color
  • NOOK Tablet
  • Tablet/Phone
  • NOOK for Windows 8 Tablet
  • NOOK for iOS
  • NOOK for Android
  • NOOK Kids for iPad
  • PC/Mac
  • NOOK for Windows 8
  • NOOK for PC
  • NOOK for Mac
  • NOOK for Web

Want a NOOK? Explore Now

NOOK Book (eBook)
$9.99
BN.com price
(Save 37%)$16.00 List Price

Overview

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.  
Read More Show Less

Editorial Reviews

Journal of the History of Biology - Nathan Crowe
Genentech: The Beginnings of Biotech paints a wonderfully detailed picture of an important beginning in the history of biotechnology.”
Technology and Culture - Lisa Onaga
“Hughes’s Genentech makes an invaluable international contribution to understanding how a period just short of a decade redefined ‘business as usual’ for biologists.”
Choice
Hughes has crafted an engaging historical account of Genentech from its beginnings as a small laboratory at the University of California, San Francisco to the 2009 merger with Roche for 47 billion dollars. . . . [Her] account will appeal to a broad audience and is a must read for scholars interested in the history of biotechnology. Highly recommended.

— J. A. Hewlett

Nature Medicine
[A]n important addition to the history of biotech.

— Phillip A. Sharp, Massachusetts Institute of Technology

Chemical Heritage Magazine
Over the past 20 years Sally Smith Hughes has done a great service to science studies by conducting in-depth oral-history interviews with prominent scientists, venture capitalists, corporate leaders, and attorneys in the history and business of early biotechnology. She drew on her unprecedented access to corporate records and a large number of actors and their oral histories to write Genentech, the first comprehensive account of the creation and early development of the Genentech Corporation.

— Doogab Yi

Nursing Standard
The author skillfully reveals the practical, day-to-day, hands-on roles played by venture capitalists focused on fiscal gain and scientists focused on scientific breakthroughs. . . . [A] fascinating read.

— Valerie McGurk

Choice - J. A. Hewlett
“Hughes has crafted an engaging historical account of Genentech from its beginnings as a small laboratory at the University of California, San Francisco to the 2009 merger with Roche for 47 billion dollars. . . . [Her] account will appeal to a broad audience and is a must read for scholars interested in the history of biotechnology. Highly recommended.”
Nature Medicine - Phillip A. Sharp
“[A]n important addition to the history of biotech.”
Chemical Heritage Magazine - Doogab Yi
“Over the past 20 years Sally Smith Hughes has done a great service to science studies by conducting in-depth oral-history interviews with prominent scientists, venture capitalists, corporate leaders, and attorneys in the history and business of early biotechnology. She drew on her unprecedented access to corporate records and a large number of actors and their oral histories to write Genentech, the first comprehensive account of the creation and early development of the Genentech Corporation.”
Nursing Standard - Valerie McGurk
“The author skillfully reveals the practical, day-to-day, hands-on roles played by venture capitalists focused on fiscal gain and scientists focused on scientific breakthroughs. . . . [A] fascinating read.”
Bulletin of the History of Medicine - Cyrus C. M. Mody
“[A]n eminently readable (and, for classes, eminently assignable) story . . . . Smith Hughes is one of the foremost oral historians of science today, and Genentech is filled with illuminating interview snippets woven artfully into a narrative that both engages and (somewhat surreptitiously) analyzes. . . . [F]or a case study that lays out in lively detail the ambiguities and exuberances of high-tech entrepreneurship, Smith Hughes’s Genentech surely ranks among the very best.”
Daniel Kevles
“Drawing extensively on oral histories, Hughes reveals the day-to-day hands-on roles of both the venture capitalists and the scientists, their eyes fixed at once on scientific triumphs and corporate riches, who brought Genentech to life. Hughes vividly recounts the tough-minded deals, buccaneering strategies, laboratory struggles, and relentless patent arrangements that not only made for Genentech’s success but that pioneered the new biotechnology industry’s operational model.”
Robert Cook-Deegan
“Sally Smith Hughes’s book on the formative years of Genentech helps fill a gaping hole in the history of biotechnology, as it grew out of the recombinant DNA technology in the 1970s and 1980s. This book covers the quake from its epicenter. It draws on two decades of research, thousands of conversations, hundreds of documents, and dozens of oral history interviews. This zippy read will be welcomed by those who care about the San Francisco Bay area, biotechnology, the history of molecular biology, and high-tech economic development. Genentech has long had its legends, statues, buildings, and view of Candlestick Park; now it has a book about its beginnings.”
Cynthia Robbins-Roth
“My first job out of my postdoc was at Genentech in early 1981. At the time, I had no idea that all those guys in suits were doing something that had never been done before. But I did know the science was amazing—and Bob Swanson was the clear leader in creating an environment that supported that science. Sally Smith Hughes has brought to life the details of what the key players were up to—they weren’t playing it safe, and they created a catalytic environment that generated a whole new industry.”
Daniel S. Greenberg
"Sally Smith Hughes skillfully describes the improbable creation, difficult adolescence, immense prosperity, and eventual foundering of Genentech, the first biotech behemoth. It’s a great tale, with a cast of fabulous characters and surprising episodes, ranging from Palo Alto to Wall Street. This is an outstanding book that should appeal to Nobel laureates as well as hedge-fund barons and ordinary citizens.”
Social History of Medicine
“[A] fascinating book, vividly recount[ing] the blood, sweat, and tears of the early days of ‘genetic engineers’ working at the bench, designing new biomolecules, and capitalizing their promises on Wall Street.”
Read More Show Less

Product Details

  • ISBN-13: 9780226359205
  • Publisher: University of Chicago Press
  • Publication date: 9/21/2011
  • Series: Synthesis
  • Sold by: Barnes & Noble
  • Format: eBook
  • Pages: 232
  • File size: 3 MB

Meet the Author

Sally Smith Hughes is a historian of science at the Bancroft Library at the University of California, Berkeley. She is the author of The Virus: A History of the Concept and the creator of an extensive collection of in-depth oral histories on bioscience, biomedicine, and biotechnology.

Read More Show Less

Read an Excerpt

Genentech

The Beginnings of Biotech
By SALLY SMITH HUGHES

The University of Chicago Press

Copyright © 2011 The University of Chicago
All right reserved.

ISBN: 978-0-226-35918-2


Chapter One

Inventing Recombinant DNA Technology

I looked at the first gels [in the first recombinant DNA cloning experiment], and I can remember tears coming into my eyes, it was so nice. I mean, there it was. You could visualize your results in physical terms, and after that we knew we could do a lot of things. Herbert W. Boyer, March 28, 1994

Modern biotechnology originated in 1973 with the invention of recombinant DNA technology, a now-universal form of genetic engineering. It entails recombining (joining) pieces of DNA in a test tube, cloning (creating identical copies of DNA) in a bacterium or other organism, and expressing the DNA code as a protein or RNA molecule. It soon vastly extended the power and scope of molecular biology, penetrated several industrial sectors, and became a cornerstone of a new industry of biotechnology. Yet technological power and potential cannot alone explain its first commercial application—at the biotechnology company Genentech in the mid-1970s. Stanley Cohen and Herbert Boyer, the two inventors, had designed the technique for basic-science research. But they immediately foresaw its practical applications in making plentiful quantities of insulin, growth hormone, and other useful substances in bacteria. Despite their common starting point, Cohen and Boyer chose different avenues for industrializing recombinant DNA technology. Why they did so was a matter of personality and professional commitments. It was also a matter of the national environment in the U.S. of the 1970s—a pivotal decade of raging debate in science politics, major dilemmas and decisions in constitutional and patent law, and cultural, attitudinal, and personal challenges as commercial interests first entered molecular biology full force.

TWO SCIENTISTS ON CONVERGING PATHS

Herbert Wayne Boyer was born in 1936 into a blue-collar family and grew up in the little town of Derry, thirty miles from Pittsburgh in the coalmining country of western Pennsylvania. His father had left school in eighth grade and eventually found work as a railroad brakeman and conductor. His mother married straight out of high school and stayed home to look after Herb and a younger sister. Herb earned pocket money by mowing lawns, delivering newspapers, and doing other odd jobs of a middle-American boyhood. He hunted and fished with his father and developed an abiding love of the outdoors. All four Boyers played at least one musical instrument and regularly got together with family and friends to play country-western music—bright spots in an otherwise workaday world. Herb's first years at Derry Borough High School were a steady round of football, basketball, baseball, and girls—anything but academic achievement. He was on "a rather perilous course of delinquency," 2 he later admitted. It took a no-nonsense football coach and teacher to jolt Herb out of his apathy. "Pat Bucci straightened me out," he subsequently observed. He began belatedly to focus on schoolwork. Coming into his own, he was elected junior- and senior-class president and voted most athletic. But the limited vistas of a small railroad town felt more and more confining. One way or another, he had to get out. Herb resolved to go on to college, the first in his family to do so. He was off to troll wider horizons but destined never to lose the down-to-earth practicality and lack of pretension of his blue-collar upbringing.

Stanley Norman Cohen is also the first child and only son of parents whose formal education ended with high school. His father was a small businessman who tried his hand, never very successfully, at several trades in and around their home in Perth Amboy, New Jersey, a town just southwest of New York City. Stan's mother worked for a time as a secretary to make ends meet. Stan was born in 1935 and raised as an only child until the birth of a sister when Stan was almost ten. Tight finances, gentle discipline, and parental ambition for their children to rise in the world largely defined home life. While Boyer needed Coach Bucci's intervention to provoke his attention to schoolwork, learning came naturally and at an early age for Cohen. No adult had to build discipline in young Stan. "I suppose," he recalled, "that overall I wasn't much of a wayward kid, so there really wasn't a lot of need for discipline." He and his father, a frustrated inventor, spent off-hours in the basement doing small wiring and mechanical projects. Cohen credits his father with sparking his interest in how things work—sparking his interest in science. From the start he was motivated to achieve, and achieve he consistently did. In high school he was editor of the school paper and associate editor of the yearbook. By then his scientific interests centered on biology, which to Stan meant becoming a physician. He now had a goal that would move him beyond the narrow scope of his upbringing. Yet he would remain stamped with the work ethic, professional ambition, and respect for knowledge of his Jewish heritage.

Boyer and Cohen, with only slightly more than a year between them, came of age in the early 1950s. Both were financially strapped; both could expect no financial assistance from their families; both chose colleges close to home. In 1954 Boyer entered Saint Vincent College, a liberal-arts institution run by Benedictine monks in Latrobe, Pennsylvania, a few easy miles from Derry. He lived at home to save money and hitchhiked or rode the bus to and from classes. His father, a railroad man, refused to learn to drive, let alone to buy a family car. Boyer majored in biology and chemistry, intending to go on to medical school. A chance class assignment suggested another direction. More than five decades later, Boyer recalled the shift with the clarity of a formative moment:

We had a brand-new, shiny [cell physiology] textbook with a blue and white cover. Each of us was assigned a chapter, and we had to give a seminar on it. Which one did I get? "The Structure of DNA." This was 1957, and the buzz of DNA was just getting into the textbooks.... I was really taken with the Watson-Crick structure of DNA and this started my fascination with the heuristic value of the structure.

A sign of his new infatuation was Boyer's Siamese cats, Watson and Crick. In 1958 Saint Vincent awarded Boyer a bachelor's degree in biology and chemistry.

Boyer applied and failed to enter medical school, a D in metaphysics being his nemesis. He settled on graduate school at the University of Pittsburgh, partly to improve his grades and reapply to medical school, partly because "a small-town boy doesn't stray too far from home." He craved intellectual stimulus and found it in the heady research of a bacterial genetics laboratory at a watershed moment in molecular biology. Watson and Crick's discovery of 1953 had launched an avalanche of work on major questions—prime among them, the nature of the genetic code and the mechanism of protein synthesis. Much of this research transpired in bacteria, employed by experimentalists for their relative simplicity as compared to the animal kingdom. Boyer thrived on the lab's scientific ferment and freeform discussion on genetic exchange and recombination in bacteria. "That [lab]," Boyer recalled, "was my [scientific] awakening."

In 1959, at the end of his first year of graduate school, Boyer married his high school sweetheart, Marigrace Hensler, a biologist in her own right. She gamely supported the couple, as Boyer tackled a nearintractable experiment on deciphering the genetic code. Breaking the code was the foremost problem in molecular biology of the day, one that only a supremely ambitious—or naive—graduate student would agree to take on. Boyer did and plugged away, even after two biochemists broke the code in 1961. "Boyer," a future colleague commented, "consistently tried big things without knowing whether they could or should work." He managed to squeeze out enough data to complete a dissertation. His attraction to challenging problems would become a mark of his professional career. Boyer was setting an enduring pattern. Below the casual surface lay ambition and tenacity. In 1963 Boyer earned a doctoral degree in bacteriology.

Cohen chose Rutgers University, a few short miles from Perth Amboy. Rutgers offered the most scholarship support and was close to his ailing father. Studious as ever, Cohen worked hard but carried to extremes his resolve to make a life beyond academics. He joined the university debating team, took up the guitar, and tried his hand at writing pop songs, one of which reached the hit parade. This flurry of extracurricular activities, predictive in its intensity, failed to dent his academic performance. In 1956 he graduated magna cum laude from Rutgers. That fall Cohen entered medical school at the University of Pennsylvania, a major draw being the substantial scholarship funds it provided. His first taste of basic research in the second year led to a summer research position in London and to the publication of his first paper. He took time off that summer to wander the cafés of Europe, supporting himself by singing and strumming the banjo. "It was a wonderful time," he recalled, remembering the freedom and lack of responsibility. Life from then on would never again be as carefree, but banjo and song would remain outlets for life. In 1960 Cohen graduated from Penn with a degree in medicine. Within a whirlwind five-year period, swinging from the East Coast to the South, Cohen completed an internship, a two-year research position at the National Institutes of Health (NIH), and a residency in medicine. In 1961 he married Joanna Wolter, and they eventually had two children.

Boyer's career took a less peripatetic course. He went straight from Pittsburgh to Yale as a postdoctoral fellow in microbiology. There he joined a lab focused on genetic exchange and recombination in bacteria. He became fascinated with the restriction enzymes of bacteria—enzymes that cut up and destroy foreign DNA entering the bacterial cell. The word just emerging in the 1960s was that certain types of restriction enzymes sever DNA at unique sequences in the molecule. Perhaps, Boyer and others recognized, one could use these strange enzymes to clip DNA into well-defined fragments and map its structure. He suspected early on that restriction enzymes were going to be "very helpful enzymes" for the precision cutting, recombination, and characterization of DNA. The suspicion was prophetic: his career-long passion would become restriction enzyme research and genetic manipulation. Boyer now lived and breathed his science. After a night on the town, he would return to the lab or rise in the dark to observe an experiment. But the folks at home were stymied. "What are you doing?" his father would ask. "Restriction endonuclease modification," he would glibly answer, using the technical term for his research area. He would then pause for his father's inevitable retort, "Well, what good is it? What are you going to do with that?" Boyer would respond, "I don't know—cure the common cold." His answer was dismissive, but his father's question prompted him to ponder the practical utility of his research.

Cohen meanwhile had begun a postdoctoral research fellowship (1965–67) in molecular biology at Albert Einstein College of Medicine in New York. It was here he stopped wavering between a career in medicine or science. He decided to pursue both, apparently expecting the rewards of a dual career to outbalance its tensions and frantic pace. He took up research on plasmids, tiny rings of DNA in the cytoplasm of bacterial cells that reproduce outside the main chromosome. Plasmids typically carry antibiotic resistance genes that can pass from one bacterium to another, spreading the resistance problem. The study of plasmids was at the time a quiet backwater and to Cohen consequently appealing. Scientists interested in genetic exchange and gene regulation mainly studied viruses, which had been a central focus of molecular studies from the 1930s on. Cohen reasoned that his heavy clinical responsibilities would make successful competition with "hotshot" molecular biology labs difficult if not impossible. Plasmid research seemed a perfect fit: he knew the necessary molecular and biochemical techniques, and the growing medical problem of antibiotic resistance was an appropriate topic for a physician. He was correct in every regard except for expecting the field to remain tranquil. It was about to explode, and Cohen would find himself at its epicenter.

By 1968 Cohen was intent on finding a faculty position. One of his mentors had collegial associations with several members of the biochemistry department at Stanford University. The connections led to a job offer, but not in biochemistry. Some years earlier, the clinical departments at Stanford Hospital in San Francisco had moved south to join the preclinical departments on Stanford's Palo Alto campus—a reorganization aimed at bringing basic science and clinical medicine into geographic and intellectual proximity. Recognizing Cohen as one of a new breed of physician-scientists the school sought to attract, the Department of Medicine offered Cohen an assistant professorship in its Division of Hematology. Cohen, drawn by the California climate and lifestyle, accepted and in 1968 moved with his wife to the sun-swept campus in Palo Alto.

He was disheartened to find that no one in the department shared his fascination with molecular genetics. He turned for advice to Arthur Kornberg, the powerful chairman of Stanford's biochemistry department. By virtue of his Nobel Prize, academic position, and forceful personality, Kornberg was a figure to reckon with. Not one to mince words, he told Cohen that plasmid research was an uninteresting line of investigation. The irony of the remark would soon become apparent. "So this wasn't a very comforting introduction to Stanford," Cohen recalled. His understatement skated over what must have been an unsettling blow: he had come to Stanford considering that shared scientific interests and collegial ties might lead to a joint appointment in the Department of Biochemistry. Instead, Kornberg made it clear that Cohen's association with the department was at best to be informal. Kornberg almost never granted joint appointments and also believed that only a rare individual could optimally perform both clinical medicine and basic research. Despite the tepid welcome and even after his own lab was operating, Cohen, according to biochemist Paul Berg, "hung around in [the Department of] Biochemistry most of the time."

Berg exaggerated, but Cohen indeed thrived on the department's stimulating intellectual exchange and had access to its electron microscope and other equipment lacking in his home department. He regularly attended biochemistry seminars and benefited from the chance "to bounce ideas off people in that department." He particularly profited from discussing ongoing departmental research on DNA ligation (joining) and DNA uptake by animal cells. In turn, he shared with biochemistry colleagues his work on plasmid isolation and characterization. But the research Cohen published in the early 1970s was not done in collaboration with Stanford biochemistry faculty. As he stated forcefully in 2010: "Notwithstanding Kornberg's notion that all important scientific knowledge at Stanford originated in the Department of Biochemistry, the work on DNA replication in that department had absolutely zero impact on my research. Similarly, the work on biochemical methods of dAT joining"—a biochemical method for joining DNA fragments—"by Berg and others did not impact my work."

(Continues...)



Excerpted from Genentech by SALLY SMITH HUGHES Copyright © 2011 by The University of Chicago. Excerpted by permission of The University of Chicago Press. All rights reserved. No part of this excerpt may be reproduced or reprinted without permission in writing from the publisher.
Excerpts are provided by Dial-A-Book Inc. solely for the personal use of visitors to this web site.

Read More Show Less

Table of Contents

PrologueAcknowledgments1/        Inventing Recombinant DNA Technology            Two Scientists on Converging Paths            The Collaboration            Patenting and Politics            Steps toward Commercialization2 /        Creating Genentech            Bob Swanson            Founding Genentech            Legal and Political Obstacles            A Full Business Plan3 /        Proving the Technology            A Portentous Experiment            Switching Targets            Negotiating Research Agreements            Making Somatostatin            Wider Issues    4 /        Human Insulin: Genentech Makes its Mark            Seeking Corporate Contracts            Procuring a Facility and Staff            Genentech’s Human Insulin Project            The Eli Lilly Contract            Publicity and Expansion            5 /        Human Growth Hormone: Shaping a Commercial Future            Competing for Human Growth Hormone            Moving toward Corporate Integration            Scaling Up Insulin and Growth Hormone            Corporate Expansion            An Emerging Culture     6 /        Wall Street Debut            Biomania            Exit Strategies            Interferon: The New Wonder Drug?            Run-up to an Initial Public Offering            Legal Impediments                    The IPO           EpilogueNotesBibliographyOral History BibliographyIndex
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)